Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 9 Saturday Sunday Monday MONDAY, DECEMBER 9 TH 6:00pm - 8:00pm Pacific Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4838 BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic AntiCD7 CAR-T-Cells Diorio C Shaughnessy P, Farhadfar N Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4837 Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/ Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel) Shah BD Pantin J, Shaughnessy P Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4743 MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Pianko M Ramakrishnan A, Multiple Myeloma: Pharmacologic Therapies: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4828 A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort Dholaria BR Ramakrishnan A, Cruz JC Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4829 CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies Ghobadi A Shaughnessy P Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4845 Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe- cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial Roddie C Shaughnessy P Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4911 Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis Soiffer RJ Shaughnessy P Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4600 Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/ Neoplasms: Final 5-Year Data Cortes JE Donnellan WB Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III